EU First For Pegfilgrastim Biosimilars? EMA Decides This Week
Executive Summary
Two biosimilar versions of Amgen’s blockbuster drug, Neulasta, are up for an opinion from the European Medicines Agency this week on whether they should be approved in the EU. Coherus is the sponsor of one of the products.
You may also be interested in...
Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy
Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.
Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy
Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.
EMA ‘Yes’ For Pegfilgrastim Biosimilars Spells End For Neulasta’s EU Stronghold
Approval of the first pegfilgrastim biosimilars in the EU would mark the start of a period of accelerated sales declines for Amgen's Neulasta but the outlook for the blockbuster bio-originator is not necessarily bleak.